We previously showed that outcome of pediatric 11q23/MLL-rearranged AML depends on the translocation partner (TP). In this multicenter international study on 733 children with 11q23/MLL-rearranged AML, we further analyzed which additional cytogenetic aberrations (ACA) had prognostic significance. ACAs occurred in 344/733 (47%) and were associated with unfavorable outcome (5-year overall survival (OS) 47% vs. 62%, P<0.001). abnormalities, was present in 26% (n=192/733), and showed worse outcome than those without complex karyotype (OS 45% vs. 59%, P=0.003) in univariate analysis only. In conclusion, like TP, specific ACAs have independent prognostic significance in pediatric 11q23/MLL-rearranged AML, and the mechanism underlying these prognostic differences should be studied.
Introduction
Pediatric acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease. In addition to initial response to treatment, prognosis is largely determined by the presence of cytogenetic abnormalities and genetic lesions. [1] [2] [3] [4] [5] [6] Several recurrent cytogenetic abnormalities, such as 11q23/MLL-rearrangements, predict outcome in myeloid neoplasms and acute leukemia. 7 So far, more than 60 different translocation partners (TP) have been identified, and new partners are still being reported to add to the diversity of MLL-rearranged leukemia. 8, 9 A recent international study highlighted the heterogeneity of 11q23/MLLrearranged pediatric AML by showing that outcome is dependent on TP. 10 This study also revealed that additional cytogenetic aberrations (ACAs) were an independent adverse prognostic factor, 10 but so far, it is unknown which additional aberration(s) determine this unfavorable outcome signature.
A recent large study in an adult AML cohort showed that additional cytogenetic abnormalities in t(9;11)(p22;q23) AML did not affect outcome. 11 However, the BerlinFrankfurt-Münster (BFM) group showed that children with t(9;11)(p22;q23) with additional aberrations had lower rates of overall survival (OS) than those with other subgroups of AML. 6 To date, no large studies have been undertaken to study the prognostic relevance of specific ACAs in pediatric MLL-rearranged AML. In this multicenter international study, we retrospectively analyzed data from a large cohort (n = 733) to determine which ACAs contribute to the prognostic effect in pediatric MLL-rearranged AML.
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Patients and Methods

Patients
Patients' data collected in the retrospective international study by Balgobind et al. 10 were included in this study. In summary, data from 756 patients with 11q23/MLL-rearranged pediatric AML were collected from 11 collaborative study groups -the BFM Study Group (Germany and Austria); the Japanese Pediatric Leukemia/Lymphoma Study Group (Japan); To analyze ACAs, data from all patients with incomplete karyotypes were excluded.
For all cases included in the analysis, the number of aberrations was counted. Each aberration separated from the rest of the karyotype by a comma was counted as one abnormality (regardless of its complexity), counting every aberration only once (if present in multiple clones), and excluding constitutional aberrations. Triploidy and tetraploidy were counted as 1 aberration (1 event). In this cohort of 11q23/MLL-rearranged cases, ACAs cases were defined as having 2 or more aberrations, including the 11q23/MLL-rearrangement (n = 344). All cases with 3 or more aberrations were considered having a complex karyotype, consistent with previously used definitions. 24, 25 Numerical aberrations were defined as loss or gain of a full chromosome. Balanced translocations were defined as translocations in which no material seemed to be gained or lost as determined by conventional karyotyping. Structural aberrations were defined as aberrations resulting from breakpoints within a chromosome. In all unbalanced translocations we described which material was lost and gained and also whether 11q23 was involved. The presence of a balanced overall karyotype was defined as a karyotype with two complete copies of all autosomes and complete copies of sex chromosomes without any additional material (2n). Definitions used for cytogenetic classification are summarized in Supplementary Table S1 .
Statistical analyses
Complete remission (CR) was defined as less than 5% blasts in the bone marrow, with regeneration of trilineage hematopoiesis plus absence of extramedullary disease. 26 Early death was defined as any death within the first 6 weeks of treatment. Treatment of patients who did not obtain CR within the specified time-period in the protocol, was considered a failure on day 0. OS was measured from the date of diagnosis to the date of last follow-up or death from any cause. Event-free survival (EFS) was calculated from the date of diagnosis to the first event or to the date of last follow-up. Events included nonremittance, relapse, secondary malignancy, or death from any cause. 
Results
Distribution of additional cytogenetic aberrations (ACAs)
Of the 756 patients, 733 (97%) had complete karyotypes and their data were included in the study (see flowchart in Figure 1 ). There were no significant differences in the patients included (n = 733) and not included (n = 23) in this study with respect to sex, age, WBC count, and TP group (data not shown). ACAs were found in 344 of 733 cases (47%) ( Figure   1 ). The number of additional aberrations ranged from 0 to 15 (mean, 1.2 additional aberrations; Supplementary Figure S1 ). Tables 1 and 2 show the distribution of ACAs by translocation partner (TP) group and clinically relevant parameters [sex, age, WBC count, and FAB (French-American-British) subtype]. TP groups 9p22 and 19p13 were characterized by a relatively high frequency of numerical ACAs, whereas groups 10p12, 10p11.2, and 4q21 showed higher prevalence of structural ACAs (P < 0.001) ( Table 1) . Also, there were significant differences in the number of aberrations among TP groups: the 6q27 group had a relatively high number of ACAs (P = 0.002) whereas groups 9p22, 19p13, and 1q21 had a lower number of ACAs (Table 2) .
Distribution of ACAs in clinically relevant groups
ACAs were less likely to occur in young children (<2 years old) than in children 2-9 years old or 10 years or older (42% vs. 53% vs. 51%, P = 0.02, Table 1 ). However, structural ACAs were more frequent children <2 years than in children 2-9 years old or 10-18 years For personal use only. on June 7, 2017. by guest www.bloodjournal.org From (48% vs. 30% vs. 31%, P < 0.01) ( Table 1 ). There was a higher prevalence of highly complex karyotypes (>5 aberrations) in children 10-18 years old than those younger than 2 years or 2-9 years old (11% vs. 4% vs. 5%, P = 0.02, Table 2 ).
Although the number of patients with FAB M7 was small, ACAs were more likely to occur in patients with AML FAB M7 as compared to those with other FAB types (79% vs.
46%, P = 0.008), whereas patients with AML FAB M2 and M4 had the lowest occurrence of ACAs (Table 1) . Also, patients with AML FAB M7 seem to have a higher number of aberrations than those with other FAB morphologies (P = 0.003) ( Table 2 ).
Specific recurrent aberrations
Trisomy 8 was the most frequently occurring numerical abnormality (130/733, 18% of all cases and 38% of ACA cases, Figure 2A ). In addition, trisomy 4, 6, 13, 19 and 21 were recurrent ACAs (at least 15 cases each). Two cases with Down's syndrome were included in this study. However, since constitutional aberrations were not included in the additional aberrations, they were not included in the trisomy 21 group. Only 11 patients had losses of full chromosomes, collectively accounting for 25 monosomies (Figure 2A ). Figure 2B shows the collective analysis of structural ACAs per chromosome arm, but does not include breakpoints involved in balanced 11q23/MLL-translocations. However, the figure includes unbalanced 11q23/MLL-translocations in which chromosomal material was lost or gained. Chromosomes 1 and 11 were most frequently involved in structural ACAs.
Analysis of specific breakpoints showed that 11q23 was the only breakpoint found more than 10 times (data not shown).
Univariate analysis of the prognostic impact of ACAs on survival
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vs. 48%, P = 0.002; OS 47% vs. 62%, P < 0.001) (Figure 3) . CIR estimates of patients with ACAs were significantly higher than for those without ACAs (52% vs. 38%, P < 0.001; Figure 3 ).
Patients with complex karyotypes had significantly worse outcomes than those without complex karyotypes (EFS 37% vs. 46%, P = 0.02; OS 45% vs. 59%, P = 0.003; CIR 53% vs. 42%, P < 0.001; Figure 3 ).
The presence of trisomy 8 (n = 130) was a favorable prognostic factor (EFS 53% vs.
29% for patients without trisomy 8, P < 0.001; OS 61% vs. 39% for patients without trisomy 
weeks after diagnosis, P = 0.04) rather than relapse. In addition, patients with trisomy 19 had a significantly higher incidence of early death (16% vs. 3.3% in other ACA cases, P = 0.004), which could not be explained by adverse clinical prognostic factors such as high WBC or age.
Structural aberrations were diverse and randomly distributed among translocation partner groups, and survival analysis of patients with specific breakpoints was not feasible because none of the breakpoints was involved more than 10 times. Table 4 summarizes results of the multivariate survival analysis. Cox proportional hazards model for EFS, OS, and relapse incidence of the full cohort (n = 733) showed that trisomy 8 and trisomy 19 were independent prognostic factors at P < 0.05 for EFS (HR 0.57, P = 0.02 and HR 1.77, P = 0.01) and OS (HR 0.54, P = 0.03 and HR 2.11, P = 0.002) ( Table 4) .
Multivariate analyses of the prognostic impact of ACAs on survival
Structural aberrations as a general finding predicted EFS (HR 1.39, P = 0.01) ( Table 4 ). The translocation partners identified by Balgobind et al. 10 (10p12, 6q27, 1q21 and 10p11.2) remained significant independent prognostic factors in these models. Trisomy 8, 19, and 21
were not significant factors in the model for the prediction of relapse incidence. Complexity of the karyotype, tested by different cut-off values (2 or more aberrations, 3 or more aberrations, and more than 5 aberrations), was not a significant factor for outcome in all models and was therefore excluded from the final model. A separate analysis of t(9;11)(p22;q23) cases showed that they did not differ considerably from the complete cohort (Supplementary Figure S2 , Supplementary Table S2 ).
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Discussion
The heterogeneity of pediatric AML is mainly determined by specific karyotypes and molecular aberrations which have become important prognosticators. 1, [3] [4] [5] [6] 8, 11, [27] [28] [29] [30] [31] [32] [33] In addition, within distinct groups such as 11q23/MLL-rearranged AML, we have reported that additional cytogenetic aberrations are of prognostic relevance. 10 In the present exploratory study, we identified trisomy 8, trisomy 19, and trisomy 21 to be recurrent ACAs of prognostic significance in pediatric 11q23/MLL-rearranged AML. Multivariate analysis showed that only trisomy 8 and trisomy 19 as additional aberrations were of independent prognostic value.
Notably, the adverse outcome for 11q23/MLL-rearranged AML patients harboring trisomy 19 was due to refractory disease and early death rather than an increased rate of relapse.
Complex karyotype was a frequent finding (26%) and a negative prognostic factor in univariate analysis only.
Trisomy 19 in AML is an aberration that is rarely found as the sole aberration. 34 In infants with AML it is associated with t(7;12)(q36;p13) and t(7;12)(q32;p13). 35 In most of such cases it can seem to be the sole aberration due to the cryptic t(7;12). 35 Trisomy 19 has been described as an additional aberration with adverse prognostic significance in adult 11q23/MLL-rearranged AML. 11 It has been postulated that a gene dosage effect of the DNA methyltransferase 1 (DNMT1) located on 19p13.2 contributes to the hypermethylation seen in patients with MDS and thereby to prognosis. 36 Future studies may reveal whether this mechanism also contributes to aberrant methylation found in pediatric 11q23/MLL-rearranged AML.
37
In our study, trisomy 8 was found to be an independent favorable prognostic factor. in these studies, which is comparable to the EFS obtained our study. Alternatively, a strong negative association between monosomal karyotype, defined as a karyotype with at least 2 monosomies or 1 monosomy combined with at least 1 structural aberration, and outcome was described in adult AML. 45 This monosomal karyotype was only present in 1.5% (n = 11) of our cases and therefore it was not possible to evaluate the predictive value in our pediatric 11q23/MLL-rearranged AML cohort.
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A limitation of our study is the variety of treatment regimens, although all protocols had a backbone including intensive chemotherapy with cytarabine/ anthracycline.
Unfortunately numbers were too small to do specific analyses for different protocols, or to draw any meaningful conclusion regarding provided treatment and outcome.
In separate analysis of t(9;11)(p22;q23) cases, we confirmed most of the findings from the complete cohort, regarding frequent recurrent aberrations and predictive factors. In addition, FAB M5 morphology was still recognized as independent favorable prognostic factor in this group of patients.
In conclusion, in this exploratory study we have identified specific ACAs as novel independent prognostic variables in pediatric 11q23/MLL-rearranged AML, which can be identified by conventional karyotyping. Future studies should be aimed to test the associations found in this study in different patient cohorts. Our findings may also guide further studies that unravel the biological differences that determine outcome differences in 11q23/MLLrearranged AML as well as future treatment stratification. 
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